The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
In Vitro Model of Metastasis to Bone Marrow Mediates Prostate Cancer Castration Resistant Growth through Paracrine and Extracellular Matrix Factors
Open accessAbstract
The spread of prostate cancer cells to the bone marrow microenvironment and castration resistant growth are key steps in disease progression and significant sources of morbidity. However, the biological significance of mesenchymal stem cells (MSCs) and bone marrow derived extracellular matrix (BM-ECM) in this process is not fully understood. We therefore established an in vitro engineered bone marrow tissue model that incorporates hMSCs and BM-ECM to facilitate mechanistic studies of prostate cancer cell survival in androgen-depleted media in response to paracrine factors and BM-ECM. hMSC-derived paracrine factors increased LNCaP cell survival, which was in part attributed to IGFR and IL6 signaling. In addition, BM-ECM increased LNCaP and MDA-PCa-2b cell survival in androgen-depleted conditions, and induced chemoresistance and morphological changes in LNCaPs. To determine the effect of BM-ECM on cell signaling, the phosphorylation status of 46 kinases was examined. Increases in the phosphorylation of MAPK pathway-related proteins as well as sustained Akt phosphorylation were observed in BM-ECM cultures when compared to cultures grown on plasma-treated polystyrene. Blocking MEK1/2 or the PI3K pathway led to a significant reduction in LNCaP survival when cultured on BM-ECM in androgen-depleted conditions. The clinical relevance of these observations was determined by analyzing Erk phosphorylation in human bone metastatic prostate cancer versus non-metastatic prostate cancer, and increased phosphorylation was seen in the metastatic samples. Here we describe an engineered bone marrow model that mimics many features observed in patients and provides a platform for mechanistic in vitro studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Secretion of elevated levels of IL-6 by MSC has been detected upon interaction with malignant cells in several epithelial, hematopoietic and mesenchymal cancers (Table 2) [43, 69, 76, 77, 82, 115–119].”
From Mesenchymal stem cell secretome and regenerative therapy after cancer (2013) · cites this paper as [119]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Lee, S. O., Lou, W., Johnson, C. S., Trump, D. L., & Gao, A. C. (2004) · The Prostate · doi:10.1002/pros.20045 · Cited by 81
RetractedSilk matrix for tissue engineered anterior cruciate ligaments
Altman, G. H., Horan, R. L., Lu, H. H., Moreau, J., Martin, I., Richmond, J. C., & Kaplan, D. L. (2002) · Biomaterials · doi:10.1016/s0142-9612(02)00156-4 · Cited by 863
Self-citationOsteoblasts in prostate cancer metastasis to bone
Logothetis, C. J., & Lin, S.-H. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1528 · Cited by 614
Chen, X.-D., Dusevich, V., Feng, J. Q., Manolagas, S. C., & Jilka, R. L. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.070725 · Cited by 350
Härmä, V., Virtanen, J., Mäkelä, R., Happonen, A., Mpindi, J.-P., Knuuttila, M., Kohonen, P., Lötjönen, J., Kallioniemi, O., & Nees, M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010431 · Cited by 344
Androgen receptor and growth factor signaling cross-talk in prostate cancer cells.
Zhu, M.-L., & Kyprianou, N. (2008) · Endocrine Related Cancer · doi:10.1677/erc-08-0084 · Cited by 286 · cited 1×
“Other methods of androgen independent growth include the activation of mitogenic pathways and transcription factors such as MAPK, PI3K, STAT3, and b-Catenin [11,12].”
MethodPAK1 phosphorylation of MEK1 regulates fibronectin-stimulated MAPK activation
Slack-Davis, J. K., Eblen, S. T., Zecevic, M., Boerner, S. A., Tarcsafalvi, A., Diaz, H. B., Marshall, M. S., Weber, M. J., Parsons, J. T., & Catling, A. D. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200212141 · Cited by 279
Murillo, H. (2001) · Endocrinology · doi:10.1210/en.142.11.4795 · Cited by 263
The Role of αvβ3 in Prostate Cancer Progression
Cooper, C. R., Chay, C. H., & Pienta, K. J. (2002) · Neoplasia · doi:10.1038/sj.neo.7900224 · Cited by 238
Charafe‐Jauffret, E., Tarpin, C., Bardou, V., Bertucci, F., Ginestier, C., Braud, A., Puig, B., Geneix, J., Hassoun, J., Birnbaum, D., et al. (2004) · The Journal of Pathology · doi:10.1002/path.1515 · Cited by 199
Yuan, T.-C., Veeramani, S., Lin, F.-F., Kondrikou, D., Zelivianski, S., Igawa, T., Karan, D., Batra, S. K., & Lin, M.-F. (2006) · Endocrine-Related Cancer · doi:10.1677/erc.1.01043 · Cited by 169
Crosstalk between the Androgen Receptor and β-Catenin in Castrate-Resistant Prostate Cancer
Wang, G., Wang, J., & Sadar, M. D. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1718 · Cited by 168
Mostaghel, E. A., & Nelson, P. S. (2008) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.01.003 · Cited by 141
A Novel 3-D Mineralized Tumor Model to Study Breast Cancer Bone Metastasis
Pathi, S. P., Kowalczewski, C. J., Tadipatri, R., & Fischbach, C. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008849 · Cited by 139
Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway.
Yang, J., Fizazi, K. S., Peleg, S., Sikes, C. R., Raymond, A. K., Jamal, N., Hu, M. C. ‐., Olivé, M., Martinez, L. A., Wood, C. G., et al. (2001) · PubMed · Cited by 131
Tissue-Engineered Bone Serves as a Target for Metastasis of Human Breast Cancer in a Mouse Model
Moreau, J. E., Anderson, K., Mauney, J. R., Nguyen, T., Kaplan, D. L., & Rosenblatt, M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2483 · Cited by 131
Self-citationReichert, J. C., Quent, V. M. C., Burke, L. J., Stansfield, S. H., Clements, J. A., & Hutmacher, D. W. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.06.055 · Cited by 125
Blaszczyk, N., Masri, B. A., Mawji, N. R., Ueda, T., McAlinden, G., Duncan, C. P., Bruchovsky, N., Schweikert, H.-U., Schnabel, D., Jones, E. C., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0974-3 · Cited by 66
Extracellular matrix in bone marrow can mediate drug resistance in myeloma
Vincent, T., & Mechti, N. (2005) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190500051448 · Cited by 65
Seib, F. P., Franke, M., Jing, D., Werner, C., & Bornhäuser, M. (2009) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2009.01.003 · Cited by 54
Self-citationOrozco, R. M. M., Almaraz-Pro, C., Rodríguez‐Ubreva, J., Cortés, M. A., Ropero, S., Colomer, R., López‐Ruiz, P., & Colás, B. (2007) · Neoplasia · doi:10.1593/neo.07337 · Cited by 45
Thomas, F., Holly, J. M. P., Persad, R. A., Bahl, A. K., & Perks, C. M. (2010) · The Prostate · doi:10.1002/pros.21119 · Cited by 41
Shigemura, K., Isotani, S., Wang, R., Fujisawa, M., Gotoh, A., Marshall, F. F., Zhau, H. E., & Chung, L. W. K. (2009) · The Prostate · doi:10.1002/pros.20944 · Cited by 36
Seib, F. P., Müller, K., Franke, M., Grimmer, M., Bornhäuser, M., & Werner, C. (2009) · Tissue Engineering Part A · doi:10.1089/ten.tea.2008.0600 · Cited by 28
Self-citationLee, J., Steelman, L. S., & McCubrey, J. A. (2005) · International Journal of Oncology · doi:10.3892/ijo.26.6.1637 · Cited by 25
Andersen, C., Bagi, C. M., & Adams, S. W. (2003) · PubMed · Cited by 21
Wang, G., Haile, S., Comuzzi, B., Tien, A. H., Wang, J., Yong, T. M. K., Jelescu-Bodos, A. E., Blaszczyk, N., Vessella, R. L., Masri, B. A., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3506 · Cited by 19
Cited by
A microfluidic 3D in vitro model for specificity of breast cancer metastasis to bone
Bersini, S., Jeon, J. S., Dubini, G., Arrigoni, C., Chung, S., Charest, J. L., Moretti, M., & Kamm, R. D. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.11.050 · Cited by 534
“Lescarbeau and colleagues showed that paracrine factors secreted by hMSCs can increase prostate cancer cell survival while the interaction with a bone marrow-like ECM can lead to cancer cell morphological changes, chemoresistance and increased levels in the phosphorylation of proteins involved in cancer-related signal…”
Mesenchymal stem cell secretome and regenerative therapy after cancer
Zimmerlin, L., Park, T. S., Zambidis, E. T., Donnenberg, V. S., & Donnenberg, A. D. (2013) · Biochimie · doi:10.1016/j.biochi.2013.05.010 · Cited by 168
“IGF1 human BM, mouse BM prostate cancer, multiple myeloma, osteosarcoma pro-survival [43, 118, 119]”
BackgroundDecellularized Extracellular Matrix for Bioengineering Physiomimetic 3D in Vitro Tumor Models
Ferreira, L. P., Gaspar, V. M., & Mano, J. F. (2020) · Trends in Biotechnology · doi:10.1016/j.tibtech.2020.04.006 · Cited by 153
Targeting Fibroblast Growth Factor Pathways in Prostate Cancer
Corn, P. G., Wang, F., McKeehan, W. L., & Navone, N. M. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1550 · Cited by 107
Bano, S., Dey, T., Sharma, S., & Kundu, S. C. (2015) · ACS Applied Materials & Interfaces · doi:10.1021/am506094c · Cited by 87
Metadata
- Authors
- Lescarbeau, R. M., Seib, F. P., Prewitz, M., Werner, C., & Kaplan, D. L.
- Affiliations
- Tufts University (US)
- Leibniz Institute of Polymer Research (DE)
- Corresponding author
- Kaplan, David L.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-08-01
- Volume
- 7
- Issue
- 8
- Pages
- e40372
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3411611
- OpenAlex
- W2042887225
- Cited by
- 29
- References
- 27
- Citations by year
- 2025: 2 · 2024: 2 · 2022: 2 · 2021: 3 · 2020: 3 · 2019: 2 · 2016: 1 · 2015: 3 · 2014: 5 · 2013: 6
- FWCI
- 3.61
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- RENATE (submittedVersion, cc-by-nc-nd)
- RENATE (cc-by)
- Funders
- Deutsche Krebshilfe
- National Institutes of Health (EB002520)
- National Institute of Biomedical Imaging and Bioengineering (P41EB002520)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- prostate cancer, bone metastasis, castration resistance, bone marrow microenvironment, mesenchymal stem cells, extracellular matrix, paracrine signaling, LNCaP cells, androgen deprivation therapy, IL-6 signaling, MAPK signaling, Akt signaling, MEK1/2 inhibition, PI3K signaling, ERK1/2 phosphorylation, chemoresistance
- MeSH terms
- Androgens, Cell Survival, Extracellular Matrix, Humans, Male, Models, Biological, Neoplasm Metastasis, Phosphorylation, Prostatic Neoplasms, Apoptosis, Bone Marrow Neoplasms, Paracrine Communication, MAP Kinase Signaling System, Cell Line, Tumor, Mesenchymal Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.